Company profile
Ocugen, Inc.
NASDAQ: OCGN · Healthcare · Biotechnology
#715 of 1,418 Healthcare companies by revenue55th-percentile growth
EA Score
44DFH 26DQ 68GM 40SS 65
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ operating margin, net margin
Methodology →Revenue TTM
$4.6M
Rev growth YoY (TTM)
-3.7%
Net income (FY)
-$67.8M
Employees
116
as of 2026-08-11
Market cap
$444.2M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.4M$4.4M2025
Net income-$67.8M-$67.8M2025
Operating income-$62.9M-$62.9M2025
Total assets$43.5M$43.5M2025
Liabilities$55.7M$55.7M2025
Equity-$12.2M-$12.2M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY23
FY23
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Ocugen, Inc.’s revenue?
Ocugen, Inc. booked $4.4M in FY2025 revenue, growing 8.8% year over year — about the middle of the pack among Healthcare companies we track, at a -1537.4% net margin.
Peers · Healthcare
Lucid Diagnostics Inc.35DPrime Medicine, Inc.37DHealthy Extracts Inc.69BLift & Co. Corp.——Arrayit Corporation——ProPhase Labs, Inc.38DNeighbors
Chester →Key facts
CEOShankar Musunuri
SectorHealthcare
IndustryBiotechnology
HeadquartersMalvern, PA
ExchangeNASDAQ: OCGN
Employees116
IPO date2014-12-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.